

# Jessica Boklan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9217192/publications.pdf>

Version: 2024-02-01

19  
papers

336  
citations

933447

10  
h-index

996975

15  
g-index

19  
all docs

19  
docs citations

19  
times ranked

727  
citing authors

#	ARTICLE	IF	CITATIONS
1	A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28787.	1.5	17
2	Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib. <i>Current Cancer Drug Targets</i> , 2021, 21, 804-811.	1.6	4
3	Diagnostic workup for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium. <i>American Journal of Hematology</i> , 2021, 96, 1491-1504.	4.1	14
4	Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma. <i>Investigational New Drugs</i> , 2020, 38, 690-699.	2.6	3
5	Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28112.	1.5	16
6	Outcomes of Hematopoietic Cell Transplantation in Patients with Germline SAMD9/SAMD9L Mutations. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2186-2196.	2.0	30
7	Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. <i>Haematologica</i> , 2019, 104, 1974-1983.	3.5	43
8	Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, e359-e370.	0.6	0
9	Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia. <i>Blood</i> , 2019, 134, 2633-2633.	1.4	0
10	Constitutional <i>SAMD9L</i> mutations cause familial myelodysplastic syndrome and transient monosomy 7. <i>Haematologica</i> , 2018, 103, 427-437.	3.5	83
11	Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib. <i>Targeted Oncology</i> , 2018, 13, 779-793.	3.6	7
12	A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27217.	1.5	6
13	A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26414.	1.5	57
14	Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 187-198.	0.8	14
15	A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. <i>Clinical Epigenetics</i> , 2017, 9, 108.	4.1	25
16	Establishment and Drug Sensitivity, Gene Expression and Epigenetic Characterization of a Pediatric Leukemia Cell Line (POETIC1) with Primary Resistance to Decitabine. <i>Blood</i> , 2014, 124, 983-983.	1.4	0
17	In Vitro Growth Inhibition, Target Modulation and Drug Synergy In Pediatric Leukemia By The Novel Proteasome Inhibitor Carfilzomib. <i>Blood</i> , 2013, 122, 2673-2673.	1.4	14
18	Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS. <i>Blood</i> , 2013, 122, 2680-2680.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML). <i>Blood</i> , 2012, 120, 1517-1517.	1.4	2